Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Merker

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|April 13, 2018
Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2Victoria Huang, Amanda L Bergner, Chris Halpin, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 3, 2015
Empagliflozin as add-on to metformin in people with Type 2 diabetesL Merker, H-U Häring, A V Christiansen, et al.
Orphanet Journal of Rare Diseases|February 1, 2021
The impact of the COVID-19 pandemic on neurofibromatosis clinical care and researchHeather B Radtke, Bonita P Klein-Tasman, Vanessa L Merker, et al.
American Journal of Medical Genetics. Part A|March 26, 2014
Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosisVanessa L Merker, Miriam A Bredella, Wenli Cai, et al.
American Journal of Medical Genetics. Part A|June 9, 2022
Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosisVanessa L Merker, Bronwyn Slobogean, Justin T Jordan, et al.
Orphanet Journal of Rare Diseases|April 16, 2025
Self-reported access to specialty clinics and receipt of health surveillance among U.S. patients with neurofibromatosis 1: a national surveyVanessa L Merker, Yidan Ma, Lori B Chibnik, et al.
Plos One|April 5, 2013
Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patientsFabio P Nunes, Vanessa L Merker, Dominique Jennings, et al.
Neurology|July 7, 2021
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNSVanessa L Merker, Andrés J Lessing, Irene Moss, et al.
The New England Journal of Medicine|June 21, 2024
Brigatinib in <i>NF2</i>-Related Schwannomatosis with Progressive TumorsScott R Plotkin, Kaleb H Yohay, Phioanh L Nghiemphu, et al.
BMC Health Services Research|November 27, 2025
An exploratory mixed-methods study of organizational health literacy in a Neurosciences Intensive Care UnitDevanshi Choksi, Akashleena Mallick, Taylor McVeigh, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|April 13, 2018
Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2Victoria Huang, Amanda L Bergner, Chris Halpin, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 3, 2015
Empagliflozin as add-on to metformin in people with Type 2 diabetesL Merker, H-U Häring, A V Christiansen, et al.
Orphanet Journal of Rare Diseases|February 1, 2021
The impact of the COVID-19 pandemic on neurofibromatosis clinical care and researchHeather B Radtke, Bonita P Klein-Tasman, Vanessa L Merker, et al.
American Journal of Medical Genetics. Part A|March 26, 2014
Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosisVanessa L Merker, Miriam A Bredella, Wenli Cai, et al.
American Journal of Medical Genetics. Part A|June 9, 2022
Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosisVanessa L Merker, Bronwyn Slobogean, Justin T Jordan, et al.
Orphanet Journal of Rare Diseases|April 16, 2025
Self-reported access to specialty clinics and receipt of health surveillance among U.S. patients with neurofibromatosis 1: a national surveyVanessa L Merker, Yidan Ma, Lori B Chibnik, et al.
Plos One|April 5, 2013
Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patientsFabio P Nunes, Vanessa L Merker, Dominique Jennings, et al.
Neurology|July 7, 2021
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNSVanessa L Merker, Andrés J Lessing, Irene Moss, et al.
The New England Journal of Medicine|June 21, 2024
Brigatinib in <i>NF2</i>-Related Schwannomatosis with Progressive TumorsScott R Plotkin, Kaleb H Yohay, Phioanh L Nghiemphu, et al.
BMC Health Services Research|November 27, 2025
An exploratory mixed-methods study of organizational health literacy in a Neurosciences Intensive Care UnitDevanshi Choksi, Akashleena Mallick, Taylor McVeigh, et al.
Pageof 8